A biotech company
treating cancer by
exploding cancer cells

Oncolyze is on a mission is to provide cancer patients with a novel therapy that selectively attacks cancer cells and pokes holes in their cell membrane, causing these cancer cells to explode and die, while leaving normal cells intact.

learn more
Access the
Investor Brief


Cancer is the second
leading cause of
death globally
Cancer kills 10 million patients yearly worldwide

The estimated total annual economic impact of cancer is more than $1 trillion globally. There are many types of cancer, but one of the deadliest is acute myelogenous leukemia (AML). Patients with this blood cancer have only a 1 in 4 chance of living for 5 years after diagnosis. As a result, there remains a significant need for more efficacious treatments.

Why patients need a
better solution?
Chemotherapy drugs attack the DNA inside cancer cells, causing them to self-destruct from within. However, they are often less specific and consequently kill normal cells as well, causing terrible side effects.
Targeted Therapies are strategically designed and more specific than chemotherapy. These drugs interact with specific targets on cancer cells, but often only block proliferation of cancer cells without killing them.
The Opportunity
Deadly
Disease
The American Cancer Society projects around 25,000 new cases of acute myelogenous leukemia (AML) each year in US. Even with many treatment options, patients with AML only have a 25% chance of 5-year survival.
Tremendous
Unmet Need
Although several new drugs have been approved by the US FDA in recent years, patients still struggle. Most of these drugs don’t effectively kill off leukemic stem cells, so the leukemia comes back quickly.
Attractive
Market Potential
The current annual cost for AML treatments ranges up to $100,000 in the US. This translates to an approximate addressable market of about $2.5B for AML, in the US alone.
Our concept is simple
We have designed an anti-cancer drug (OM-301) that combines the best of chemotherapy + targeted therapy.
The targeting piece finds a cancer-specific protein that sits on the external surface of nearly all cancer cells (HDM2) but not normal cells.
Once OM-301 finds HDM2 and anchors, the active piece pokes holes in the surface, killing the cancer cell almost instantly.
What does OM-301 do to cancer cells?
It causes them to explode.
Targeting Piece (Blue)
Active Piece (Red)
Surface HDM2 (Violet)
OM-301 attaches to the
HDM2 on the surface of
cancer cells.
Complexes of OM-301 +
HDM2 form many small
pores in cancer cells.
Pores allow fluid to rush in,
causing the cancer cells to
swell and explode!
Targeting Piece (Blue)
Active Piece (Red)
Surface HDM2 (Violet)
OM-301 attaches to the
HDM2 on the surface of
cancer cells.
Complexes of OM-301 +
HDM2 form many small
pores in cancer cells.
Pores allow fluid to rush in,
causing the cancer cells to
swell and explode!
Reasons to Join Us
Devastating
Disease
Patients with AML only have a 25%
chance of 5-year survival.
World Class
Experts
Advisors and collaborators include
leaders at the top cancer institutions.
Target Present
and Unique
HDM2 is present on the surface of
leukemic cells and leukemic stem cells!
Three Patent
Families
Growing portfolio of US and
international patent applications.
Exciting
Pre-Clinical Data
OM-301 kills leukemic cells and
leukemic stem cells in mice.
Experienced
Team
More than 200 years of biopharma
industry experience.
Oncolyze’s innovative cancer
treatment brings hope
OM-301 exploits a cell surface
protein unique to cancer cells,
like targeted therapy.
Better than chemotherapy,
because it is more specific with
less side effects anticipated
We think OM-301 is independent of
cancer genetics; it appears to work at
the surface, regardless of mutation
type.
Better than targeted therapy,
because HDM2 is present on many
types of cancer cells
OM-301 is rapidly cytotoxic (kills
cancer cells) like chemotherapy,
but from the outside!
Better than chemotherapy,
because it does not need to go
inside the cancer cell to kill it
Our leadership team brings broad life science experience across discovery, development, and commercialization
leadership
Steven J. Evans
MD
FOUNDER & CHIEF
EXECTUVE OFFICER
Alex Stojanovic
PhD
CHIEF OPERATING
OFFICER
Larry Altstiel
MD, PhD
CHIEF SCIENTIFIC
OFFICER
Barbara A. Carlin
CPA, MBA
CHIEF FINANCIAL
OFFICER
board of directors
John H Abeles
MD
FOUNDER
Alexander Zukiwski
MD
CLINICAL ADVISOR
Rosemary Mazanet
MD, PhD
CLINICAL ADVISOR
James L. Foght
PhD
BUSINESS ADVISOR
Oncolyze is advised by some of the world’s most respected thought leaders in leukemia research and therapeutics
Daniel Vonn Hoff,
MD, FACP
Professor of Medicine,
Mayo Clinic
Physician-in-Chief,
TGen
Chief Scientific Officer,
US Oncology Research
Past President,
AACR
Martin Tallman,
MD
Chief, Leukemia Service,
Memorial Sloan Kettering
Cancer Center
Professor of Medicine,
Weill Cornell Medical
School
Michael Andreeff,
MD, PhD
Chief, Section of Molecular
Hematology and Therapy,
MD Anderson
Investigator,
Venetoclax (AbbVie) trial
Guido Marcucci,
MD
Chief, Division of Leukemia
Research
Chair and Professor,
Department of Hematologic
Malignancies Translational
Science
City of Hope
Editorial Board Member,
Blood Journal
Access the
Investor Brief


Questions about this
Investment Opportunity?

For all questions, please email us or join the
discussion on SeedInvest.